Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maidal EM, Alexandri N, Smyk A, Nolting A, Montalban X, Kubala Havrdova E. Brochet B, et al. Among authors: kubala havrdova e. Neurodegener Dis Manag. 2024 Dec 16:1-12. doi: 10.1080/17582024.2024.2429970. Online ahead of print. Neurodegener Dis Manag. 2024. PMID: 39676554
Altered Steroidome in Women with Multiple Sclerosis.
Kancheva R, Hill M, Velíková M, Kancheva L, Včelák J, Ampapa R, Židó M, Štětkářová I, Libertínová J, Vosátková M, Kubala Havrdová E. Kancheva R, et al. Among authors: kubala havrdova e. Int J Mol Sci. 2024 Nov 8;25(22):12033. doi: 10.3390/ijms252212033. Int J Mol Sci. 2024. PMID: 39596101 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Among authors: kubala havrdova e. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Lipid measures are associated with cognitive functioning in multiple sclerosis patients.
Lőrincz B, Motýl J, Friedová L, Hrych D, Kubala Havrdová E, Krásenský J, Urban T, Kober T, Maréchal B, Vaněčková M, Horákova D, Vrablik M, Uher T. Lőrincz B, et al. Among authors: kubala havrdova e. Mult Scler Relat Disord. 2024 Nov;91:105879. doi: 10.1016/j.msard.2024.105879. Epub 2024 Sep 6. Mult Scler Relat Disord. 2024. PMID: 39270535 Free article.
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry.
Potuznik P, Drahota J, Horakova D, Peterka M, Mazouchova A, Matyas D, Pavelek Z, Vachova M, Recmanova E, Stetkarova I, Libertinova J, Mares J, Stourac P, Grunermelova M, Martinkova A, Adamkova J, Hradilek P, Ampapa R, Dufek M, Kubala Havrdova E, Stastna D. Potuznik P, et al. Among authors: kubala havrdova e. J Cent Nerv Syst Dis. 2024 Jul 24;16:11795735241262743. doi: 10.1177/11795735241262743. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 39055049 Free PMC article.
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.
Spelman T, Eichau S, Alroughani R, Ozakbas S, Khoury SJ, Patti F, Kubala Havrdova E, Boz C, Terzi M, Kuhle J, Grammond P, Lechner-Scott J, Gray O, Amato MP, Laureys G, Shaygannejad V, Hyde R, Wang H, Bozin I, Belviso N, Quan C, Zeng F, van der Walt A, Butzkueven H; MSBase Study Group. Spelman T, et al. Among authors: kubala havrdova e. Mult Scler J Exp Transl Clin. 2024 May 25;10(2):20552173241247182. doi: 10.1177/20552173241247182. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38800132 Free PMC article.
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Sharmin S, et al. Among authors: kubala havrdova e. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6. Epub 2024 Mar 25. Lancet Child Adolesc Health. 2024. PMID: 38547883
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Kubala Havrdova E, Trneny M, Kozak T, Burman J, Macdonell R, Torkildsen Ø, Bø L, Lehmann AK, Sharrack B, Snowden J. Kalincik T, et al. Among authors: kubala havrdova e. J Neurol Neurosurg Psychiatry. 2024 Jul 15;95(8):775-783. doi: 10.1136/jnnp-2023-332790. J Neurol Neurosurg Psychiatry. 2024. PMID: 38538060
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
Foong YC, Merlo D, Gresle M, Buzzard K, Zhong M, Yeh WZ, Jokubaitis V, Monif M, Skibina O, Ozakbas S, Patti F, Grammond P, Amato MP, Kalincik T, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Lechner Scott J, Boz C, Sa MJ, Butzkueven H, van der Walt A, Zhu C; MSBASE study group. Foong YC, et al. Among authors: kubala havrdova e. J Neurol Neurosurg Psychiatry. 2024 Jul 15;95(8):767-774. doi: 10.1136/jnnp-2023-332883. J Neurol Neurosurg Psychiatry. 2024. PMID: 38453478
55 results